Introduction
Hemophilia A is an X-linked disorder of coagulation factor VIII (FVIII). Patients with hemophilia (PWH) suffer from a bleeding tendency of various degrees. Currently, the bleeding severity is roughly classified by the residual FVIII activity of the patient. In general, patients with lower FVIII activity levels have a more severe clinical phenotype than patients with higher FVIII activity [1] . Accordingly, PWH are classified into mild (FVIII activity 6-40%), moderate (FVIII activity 1-5%) and severe (FVIII activity <1%) hemophilia A [2, 3] .
Although this classification on residual FVIII activity is associated with clinical phenotype, it
is not a precise predictor of the bleeding pattern in individual patients. Within the group of patients classified as severe hemophilia A, up to 10% of patients have a mild clinical phenotype [4, 5] , indicating that residual FVIII activity level is not the sole determinant of clinical phenotype.
Differences in bleeding phenotype within the hemophilia A classifications are not completely understood. Prothrombotic factors, FVIII half-life, genotype and fibrinolytic activity did not correlate with bleeding patterns in individual patients [6, 7] .
No information is available on the contribution of platelets to the clinical phenotype in hemophilia. In normal hemostasis, platelets and the coagulation system interact with each other to form a plug at the side of vascular damage [8] . Platelets are the most important source of negatively charged phospholipids. We hypothesized that the reduced coagulation by the absence of FVIII can be (partly) compensated by an increased platelet reactivity. Therefore, we have investigated platelet activation and platelet responsiveness to different agonists in PWH in relation to their residual FVIII activity. 
Design and Methods

Patients and setting
In severe (<1% FVIII activity), moderate (1-5% FVIII activity) and mild (6-40% FVIII activity) PWH, blood was drawn during regular visits at the Van Creveldkliniek (VCK), University Medical Center Utrecht, from the antecubital vein through 20-gauge needles, into a vacuum citrate tube. Data on residual FVIII activity, inhibitor status, annual FVIII consumption and blood group were collected from patient medical files.
All participants of the current study were aged 18 years or older. Subjects were excluded when taking non-steroidal anti-inflammatory drugs, which are known to influence platelet function. Healthy, male volunteers, of similar age served as controls. During a period of 1 year, between February 2009 and February 2010, 35 PWH and 21 healthy controls were included in this study. One PWH was excluded, because blood was erroneously stored on ice after drawing; leaving 34 PWH for analysis. Based on their residual FVIII activity levels, patients were divided into mild-moderate PWH (n=21) or severe PWH (n=13).. All participants gave written informed consent and the study was approved by the Medical Ethics Committees of the University Medical Center Utrecht and performed in accordance with the Declaration of Helsinki.
Materials
R-phycoerythrin (PE) labelled antibodies for fluorescence activated cell sorting (FACS)
analyses, raised against human P-selectin (#555524), were purchased from BD biosciences (Franklin Lakes, NJ, U.S.A). Antibodies against human Platelet Factor 4 (PF4; MAB7951, AF795), human chemokine (C-X-C motif) ligand 7 (CXCL7) (MAB393, BAF393), human chemokine (C-C motif) ligand 5 (RANTES) (MAB278, AB-278-NA) and human soluble P-DOI: 10.3324/haematol.2011.042663 selectin (DY137 Duoset) were all purchased from R&D Systems (Abingdon, U.K.). Rabbit anti-vWF propeptide and rabbit anti-vWF propeptide/biotine were prepared as described by Borchiellini et al [9] . Polyclonal rabbit anti-human von Willebrand Factor (vWF) antibodies (A0082), rabbit anti-goat horseradish peroxidase (HRP) (P0449) and streptavidin-poly-HRP (P0397) were purchased from DAKO (Glusdorp, Denmark).
For platelet responsiveness assays, adenosine diphosphate (ADP) was purchased from Roche 
Platelet activation and responsiveness
Platelet responsiveness to agonists was determined with concentration series of ADP and CRP while platelet responsiveness to inhibitors was measured with concentration series of iloprost in platelets activated with a suboptimal dose of ADP. Serial dilutions of ADP (500 µM, 50 µM, 5 µM, 500 nM, 50 nM an 5 nM) were prepared in 50 µL HEPES buffered saline (HBS; 10 mM HEPES, 150 mM NaCl, 1 mM MgSO 4 , 5 mM KCl, pH 7.4, filtered through a 0.22 µm 6 filter) with 2 µL PE labeled mouse anti-human P-selectin antibodies. Similarly, serial dilutions of CRP (2.5 µg/mL, 250 ng/mL, 25 ng/mL, 2.5 ng/mL and 250 pg/mL) were prepared in 50 µL HBS with 2 µL PE labeled mouse anti-human P-selectin antibodies.
Furthermore, a serial dilution of iloprost (250 ng/mL, 25 ng/mL, 2.5 ng/mL, 250 pg/mL, 25 pg/mL and 2.5 pg/mL) was prepared in 50 µL HBS with 5 µM ADP and 2 µL PE labeled mouse anti-human P-selectin antibodies. A negative control sample, only containing 50 µL HBS with 2 µL PE labeled mouse anti-human P-selectin antibodies, was prepared to determine the basal level of platelet activation.
The platelet activation test was initiated by addition of 5 µL fresh, citrate anticoagulated, whole blood to each sample of the serial dilutions. After 20 minutes of incubation, the samples were fixed with 500 µL 0.2% formyl saline (0.2% formaldehyde in 0.9% NaCl, filtered through a 0.22 µm filter) and kept at 4°C until analyses. All samples were analysed on a FACSCalibur flow cytometer from BD Biosciences (Franklin Lakes, NJ, U.S.A.) within one day after processing. Single platelets were gated based on forward and side scatter properties.
The mean fluorescence intensity (MFI) in the platelet gate was measured with FACS analysis.
Platelets were defined as positive for P-selectin expression when the MFI exceeded the isotype control. One individual performed all assays.
ELISA procedure
Citrated whole blood was centrifuged twice at 2000xG for 10 minutes at room temperature and the resultant plasma was collected and frozen at -80°C for evaluation. Plasma levels of soluble platelet activation markers PF4, CXCL7, soluble P-selectin (sP-sel) and RANTES, and of vWF propeptide and vWF antigen (vWF:Ag) were measured by enzyme-linked immunosorbent assay. Plasma samples of patients and controls were mixed randomly for all ELISA measurements. Each antigen was measured on a separate Nunc maxisorb ELISA plate DOI: 10.3324/haematol.2011.042663 (Thermofischer Scientific, Roskilde, Denmark). Capture antibodies, monoclonal mouse antihuman PF4 (1 µg/mL), purified monoclonal mouse anti-human CXCL7 (1 µg/mL), mouse anti-human P-selectin (1 µg/mL), purified mouse monoclonal anti-human RANTES (500 ng/mL), rabbit anti-human vWF propeptide (5 µg/mL) and polyclonal rabbit-anti-human vWF and biotinylated goat anti-human NAP-2 (50 ng/mL), were added to the corresponding plates.
After five washing steps with PBS/0.5% TWEEN detection antibodies, Rabbit anti-goat-HRP (2 µL in 13 mL) and streptavidine-poly-HRP (2 µL in 13 mL), were added for 1 hour to bind the biotin on the detection antibody. After five other washing steps, Amplex Ultrared reagent was added and fluorescence intensity was measured (emission: 490 nm; excitation: 520 nm), after 75 minutes incubation, with a Fluostar Galaxy fluorimeter from BMG Labtech GmbH (Offenburg, Germany). 
Statistical Analysis
Initial quantification of FACS data was performed in BD CellQuest Pro software, version 6.0 (BD biosciences, Franklin Lakes, NJ, USA). To determine platelet responsiveness, the concentration generating a response halfway between baseline and maximum MFI of Pselectin expressing platelets (EC50) was calculated using GraphPad Prism version 4.00 (GraphPad Software, San Diago, California, USA). The maximal effect of stimulation or inhibition is represented by the platelet response to the highest used (ant-)agonist 
Results
Baseline characteristics
Of the 34 analyzed PWH, one moderate PWH and 9 (69%) severe PWH received regular prophylaxis with FVIII concentrates. Within the group of severe PWH, 3 (23%) patients had active inhibitors during time of this study. From the severe PWH, 4 (30.8%) had a hepatitis C infection at time of inclusion. Hemophilic arthropathy was present in 12 (92.3%) severe PWH and in 9 (42.9%) mild-moderate PWH. Baseline characteristics of the study population are shown in Table 1 . Individual patient characteristics are shown in table 2.
Basal level of platelet activation
The percentage of platelets with P-selectin expression on the platelet membrane was increased in severe PWH (15.9% (10.3-21.1%)) when compared to mild-moderate PWH (8.2% (4.8-14.5%), p=0.014) and to healthy controls (6.4% (4.7-7.6%), p<0.001) ( Figure 1A) .
Similarly, platelets of severe PWH showed a significant higher P-selectin expression (6.5 To study the effect of FVIII infusion itself on platelet activation, we measured P-selectin expression in 5 severe PWH before and 15 and 60 minutes after bolus infusion of FVIII to peak levels of 1.0 U/l. No differences were found (data not shown). 
6.7)
). For these markers no significant differences were found between mild-moderate and severe PWH (Figure 2A -C).
Plasma concentrations of soluble P-selectin did not differ between PWH and healthy controls ( Figure 2D ).
Von Willebrand Factor
Severe PWH had higher vWF plasma levels (14.9 µg/mL (10.1-19.3)) than healthy controls (10.0 µg/mL (8.7-12.7); p=0.027). Mild-moderate PWH had similar levels of vWF (10.7 µg/mL (8.7-13.6); p=0.538) as healthy controls (Figure 3 ). We observed equal vWF propeptide levels for severe PWH (0.7 µg/mL (0.5-0.9)), compared to mild-moderate PWH Comparing baseline levels of platelet activation in PWH with healthy controls, we found that both platelet P-selectin expression and plasma concentrations of the soluble platelet activation markers PF4, CXCL7 and RANTES are increased in PWH. Theoretically, this increased platelet activation could partially compensate a deficiency in FVIII, by providing more negatively charged surface to enhance the constrained coagulation cascade in PWH. In line with this theory one would expect platelet activation showing the largest increase in the more severely affected patients. In our study hemophilia severity was classified based upon residual FVIII activity. Comparing platelet activation in mild-moderate and severe PWH, we indeed found a higher baseline platelet P-selectin expression in the more severe patients (residual FVIII<1%). However, for the soluble platelet activation markers PF4, CXCL7 and RANTES, no significant differences were found between mild-moderate and severe PWH.
Platelet responsiveness
In an additional analysis within the severe PWH, we classified hemophilia severity based upon annual FVIII consumption. Again, platelets P-selectin expression showed to correlate to clinical phenotype. However, to fully characterize clinical phenotype, in future studies this
should not be scored solely on FVIII consumption, but also on age of first joint bleed, joint bleeding frequency and joint damage. To exclude FVIII infusion as a cause of up-regulation DOI: 10.3324/haematol.2011.042663
14 of platelet P-selectin expression, we have measured 5 severe PWH before and 15 and 60 minutes after infusion. There was no effect of FVIII infusion on basal MFI of P-selectin on platelets.
Platelet responsiveness was triggered with increasing concentrations of ADP and CRP and activation was measured with P-selectin expression. The platelet responsiveness to both ADP and CRP did not differ in PWH when compared to controls. However, the maximal response to stimulation was different in PWH. Upon maximal stimulation with ADP, an agonist which by itself can only initiate partial platelet activation, the platelets of PWH expressed more Pselectin on the cell surface than healthy controls. However, upon maximal stimulation with CRP a smaller percentage of platelets became activated in PWH. Whether this lower response to CRP can lead to an aggravation of bleeding phenotype in individual patients, remains to be determined in future studies.
Platelets of PWH were more responsive to inhibition by iloprost as shown by the low EC50 of iloprost in PWH after suboptimal stimulation by ADP, when compared to controls. In PWH, which we have shown to have a higher baseline platelet activation and a higher maximal response to stimulation by ADP, this increased inhibitory mechanism could have developed to prevent platelet activation in the absence of vascular injury.
To our knowledge, this study provides for the first time evidence that in patients, deficiency in secondary hemostasis is associated with increased platelet activation and responsiveness. A The present study has potential limitations that should be addressed. First, to assure sufficient power for a reliable comparison, mild and moderate PWH were grouped. Second, our study is a cross-sectional analysis and clinical phenotype in the severe PWH was only based on retrospectively collected annual FVIII consumption. Third, in this study we decided to only include adult PWH. The choice of a younger population would probably have given Citrated fresh whole blood was stimulated with concentration series of ADP and CRP, and incubated for 20 minutes. For all concentrations, the percentage of platelets expressing Pselectin and the mean fluorescence intensity of these platelets were measured.
The ADP and CRP concentrations generating a half maximal mean fluorescence intensity of P-selectin expressing platelets were determined (A, D). The platelet response to the highest used ADP concentration of 500 µM and the highest used CRP concentration of 2500 ng/mL, represented by both the percentage of P-selectin expressing platelets (B,E) and the MFI of Pselectin expressing platelets (C,F), were determined.
To determine platelet responsiveness to inhibition, platelets were inhibited with a concentration series of iloprost in the presence of 5 µM ADP. After 20 minutes of incubation, the samples were fixated with 0.2% formyl saline. The iloprost concentrations generating the half maximal inhibition on mean fluorescence intensity of P-selectin expressing platelets were determined (G). The platelet response to the highest used iloprost concentration of 250 ng/mL, represented by both the percentage of P-selectin expressing platelets (H) and the MFI
